Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $3.50 billion. The enterprise value is $2.65 billion.
| Market Cap | 3.50B |
| Enterprise Value | 2.65B |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 78.86 million shares outstanding. The number of shares has increased by 34.10% in one year.
| Shares Outstanding | 78.86M |
| Shares Change (YoY) | +34.10% |
| Shares Change (QoQ) | +7.45% |
| Owned by Insiders (%) | 2.11% |
| Owned by Institutions (%) | 105.64% |
| Float | 68.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,774.14 |
| Forward PS | 2,211.30 |
| PB Ratio | 4.00 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,343.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.72, with a Debt / Equity ratio of 0.06.
| Current Ratio | 17.72 |
| Quick Ratio | n/a |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.50% and return on invested capital (ROIC) is -26.76%.
| Return on Equity (ROE) | -42.50% |
| Return on Assets (ROA) | -37.00% |
| Return on Capital (ROIC) | -26.76% |
| Revenue Per Employee | $6,807 |
| Profits Per Employee | -$811,945 |
| Employee Count | 290 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +103.44% in the last 52 weeks. The beta is 0.64, so CRNX's price volatility has been lower than the market average.
| Beta (1Y) | 0.64 |
| 52-Week Price Change | +103.44% |
| 50-Day Moving Average | 46.31 |
| 200-Day Moving Average | 35.43 |
| Relative Strength Index (RSI) | 39.80 |
| Average Volume (30 Days) | 878,700 |
Short Selling Information
The latest short interest is 4.91 million, so 6.22% of the outstanding shares have been sold short.
| Short Interest | 4.91M |
| Short Previous Month | 4.91M |
| Short % of Shares Out | 6.22% |
| Short % of Float | 7.17% |
| Short Ratio (days to cover) | 6.56 |
Income Statement
In the last 12 months, CRNX had revenue of $1.97 million and -$235.46 million in losses. Loss per share was -$3.76.
| Revenue | 1.97M |
| Gross Profit | 1.97M |
| Operating Income | -248.16M |
| Pretax Income | -235.46M |
| Net Income | -235.46M |
| EBITDA | -232.29M |
| EBIT | -235.46M |
| Loss Per Share | -$3.76 |
Balance Sheet
The company has $902.26 million in cash and $52.50 million in debt, giving a net cash position of $849.76 million or $10.78 per share.
| Cash & Cash Equivalents | 902.26M |
| Total Debt | 52.50M |
| Net Cash | 849.76M |
| Net Cash Per Share | $10.78 |
| Equity / Book Value | 874.93M |
| Book Value Per Share | 11.09 |
| Working Capital | 865.46M |
Cash Flow
In the last 12 months, operating cash flow was -$178.45 million and capital expenditures -$6.00 million, giving a free cash flow of -$184.45 million.
| Operating Cash Flow | -178.45M |
| Capital Expenditures | -6.00M |
| Free Cash Flow | -184.45M |
| FCF Per Share | -$2.55 |
Margins
Gross margin is 100.00%, with operating and profit margins of -12,571.38% and -11,928.27%.
| Gross Margin | 100.00% |
| Operating Margin | -12,571.38% |
| Pretax Margin | -11,928.27% |
| Profit Margin | -11,928.27% |
| EBITDA Margin | -11,767.53% |
| EBIT Margin | -11,928.27% |
| FCF Margin | -9,343.92% |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.10% |
| Shareholder Yield | -34.10% |
| Earnings Yield | -6.72% |
| FCF Yield | -5.27% |
Analyst Forecast
The average price target for CRNX is $62.17, which is 39.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $62.17 |
| Price Target Difference | 39.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 189.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 19.6 and a Piotroski F-Score of 2.
| Altman Z-Score | 19.6 |
| Piotroski F-Score | 2 |